Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Veltassa Konnect is here to help patients start and stay on therapy

Veltassa Konnect logo

Enroll your patients with the Veltassa Konnect Enrollment Form

VELTASSA KONNECT HELPS BY PROVIDING FULL PATIENT SUPPORT SERVICES:

support

Access & Insurance Support

  • Case Management to help patients and their healthcare providers understand patients’ insurance coverage for VELTASSA, including information on PAs and appeals
  • Counseling on financial assistance options for patients
  • Specialty pharmacy ships prescriptions to patients directly
ongoin support

Ongoing Support

  • Stay-on-Track, an adherence program, offers patients ongoing support and lifestyle tips
  • Patients can enroll online
Use of the Veltassa Konnect program is not a guarantee of payment or reimbursement. Coverage is subject to individual insurance plans, which may vary.

ENROLL YOUR PATIENTS IN VELTASSA KONNECT TODAY

Please contact Veltassa Konnect at 1-844-870-7597 for additional information about the program and how your patients can access VELTASSA. (Available Monday through Friday from 8 AM to 12 AM ET and Saturday from 9 AM to 5 PM ET.)

rx pdf

Use the Veltassa Konnect Enrollment Form to help expedite access to VELTASSA for your patients

PRIOR AUTHORIZATION

Use this form to request authorization by fax or mail when an insurer requires prior authorization of a healthcare service

VELTASSA authorized wholesalers and specialty pharmacies

Next
SEE MORE

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

top

INDICATION & Important Safety Information

Important Safety Information

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

WARNINGS AND PRECAUTIONS

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnecemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnecemia. In clinical studies, hypomagnecemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnecemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnecemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.